
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
Phase I Trials Are A Critical First Step In The Study Of Novel Cancer Therapeutic Approaches. Their Primary Goals Are To Identify The Recommended Dose, Schedule And Pharmacologic Behavior Of New Agents Or New Combinations Of Agents And To Describe The Adverse Effects Of Treatment. In Cancer Therapeutics, Such Studies Have Particular Challenges. Due To The Nature Of The Effects Of Treatment, Most Such Studies Are Conducted In Patients With Advanced Malignancy, Rather Than In Healthy Volunteers. Further, The Endpoints Of These Trials Are Usually Measures Adverse Effects Rather Than Molecular Target Or Anti-tumor Effects. These Factors Render The Design, Conduct, Analysis And Ethical Aspects Of Phase I Cancer Trials Unique. As The Only Comprehensive Book On This Topic, Phase I Cancer Clinical Trials Is A Useful Resource For Oncology Trainees Or Specialists Interested In Understanding Cancer Drug Development. New To This Edition Are Chapters On Phase 0 Trials And Immunotherapeutics, And Updated Information On The Process, Pitfalls, And Logistics Of Phase I Trials
This text investigates the methodological, logistical, and ethical frameworks required to conduct successful Phase I clinical trials within the specialized field of oncology. The authors, Christopher Twelves, Elizabeth A. Eisenhauer, and Marc E. Buyse, leverage their extensive clinical expertise to address the unique challenges of testing novel therapeutic agents in patients with advanced malignancies. The book provides a comprehensive analysis of dose-finding strategies, pharmacologic assessment, and the management of adverse effects in high-stakes drug development environments.
What You Will Find
Experts identify this work as a foundational resource for oncology trainees and clinical researchers involved in drug development. Readers frequently note the technical precision and comprehensive nature of the content, which serves as a standard reference for navigating the complexities of early-stage cancer therapeutics.
Page Count:
352
Publication Date:
2015-01-01
Publisher:
Oxford University Press
ISBN-10:
0199359024
ISBN-13:
9780199359028
No comments yet. Be the first to share your thoughts!